Stay updated on Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T18:10:25.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the addition of the study's collaborators, Genmab, and the specific trial identifier SGNTV-002. However, significant details regarding the study's objectives, treatment regimens, and inclusion/exclusion criteria have been removed.
    Difference
    22%
    Check dated 2025-04-16T13:13:35.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T06:47:22.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:53:05.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-24T20:41:18.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:46:59.000Z thumbnail image

Stay in the know with updates to Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.